{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:01:02Z","timestamp":1787065262031,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1124\/dmd.106.012781","type":"journal-article","created":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T20:33:12Z","timestamp":1171571592000},"page":"795-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Reduction of Site-Specific CYP3A-Mediated Metabolism for Dual Angiotensin and Endothelin Receptor Antagonists in Various in Vitro Systems and in Cynomolgus Monkeys"],"prefix":"10.1016","volume":"35","author":[{"given":"Hongjian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"D\u2019Arienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Ewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natesan","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chyi","family":"Shyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Griffith","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.106.012781_bib1","first-page":"47","article-title":"Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general","volume":"2","author":"Boxenbaum","year":"1999","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/dmd.106.012781_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1124\/dmd.106.009977","article-title":"Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes","volume":"34","author":"Carr","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib3","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1023\/A:1016169202830","article-title":"Comparison of oral absorption and bioavailability of drugs between monkey and human","volume":"19","author":"Chiou","year":"2002","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.012781_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.012781_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2125.1998.00679.x","article-title":"Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes","volume":"45","author":"Eagling","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.106.012781_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","article-title":"Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women","volume":"13","author":"Floyd","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.106.012781_bib7","first-page":"78","article-title":"The validity of using parent compounds as standard for the quantitation of metabolites","volume":"35","author":"Fura","year":"2003","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.106.012781_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00008571-200103000-00002","article-title":"Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene","volume":"11","author":"Gellner","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.106.012781_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/00003088-200342110-00003","article-title":"Factors affecting the clinical development of cytochrome P450 3A substrates","volume":"42","author":"Gibbs","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.106.012781_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0009-2797(97)00068-9","article-title":"Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species","volume":"106","author":"Guengerich","year":"1997","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.106.012781_bib11","series-title":"Cytochromes P450; Structure, Mechanism, and Biochemistry","first-page":"473","article-title":"Human cytochromes P450","author":"Guengerich","year":"1995"},{"key":"10.1124\/dmd.106.012781_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1054-3589(08)60200-8","article-title":"Role of cytochrome P450 enzymes in drug-drug interactions","volume":"43","author":"Guengerich","year":"1997","journal-title":"Adv Pharmacol"},{"key":"10.1124\/dmd.106.012781_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig","year":"1993","journal-title":"J Am Med Assoc"},{"key":"10.1124\/dmd.106.012781_bib14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/dmd.104.000125","article-title":"Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations","volume":"32","author":"Jones","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00498250410001685755","article-title":"Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans","volume":"34","author":"Kanazu","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.106.012781_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199427010-00001","article-title":"Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences","volume":"27","author":"Kivisto","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.106.012781_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.106.012781_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/med.1016","article-title":"Role of drug metabolism in drug discovery and development","volume":"21","author":"Kumar","year":"2001","journal-title":"Med Res Rev"},{"key":"10.1124\/dmd.106.012781_bib19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.106.012781_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/abbi.1999.1506","article-title":"Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver","volume":"372","author":"Mankowski","year":"1999","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.106.012781_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s11095-006-9663-4","article-title":"Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations","volume":"23","author":"Mohutsky","year":"2006","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.012781_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/jm049548x","article-title":"Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2\u2032-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics","volume":"48","author":"Murugesan","year":"2005","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.106.012781_bib23","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1021\/jm020138n","article-title":"Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists","volume":"45","author":"Murugesan","year":"2002","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.106.012781_bib24","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1124\/dmd.106.010777","article-title":"A theoretical validation of the substrate depletion approach to determining kinetic parameters","volume":"34","author":"Nath","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1124\/dmd.30.7.831","article-title":"Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach","volume":"30","author":"Obach","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.012781_bib27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.012781_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.106.012781_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00008571-199402000-00002","article-title":"Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver","volume":"4","author":"Schuetz","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.106.012781_bib30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0090-9556(25)06821-7","article-title":"Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey","volume":"23","author":"Sharer","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002040050403","article-title":"Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans","volume":"71","author":"Shimada","year":"1997","journal-title":"Arch Toxicol"},{"key":"10.1124\/dmd.106.012781_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.012781_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.106.012781_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-3565(25)22836-1","article-title":"Use of midazolam as a human cytochrome P450 3A probe: II. characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation","volume":"271","author":"Thummel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.106.012781_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/A:1023433502647","article-title":"Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate","volume":"20","author":"Tolle-Sander","year":"2003","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/dmd.106.012781_bib36","first-page":"82","article-title":"Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics","volume":"29","author":"Ward","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1124\/dmd.32.2.172","article-title":"Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein\/CYP3A-limited bioavailability in the monkey","volume":"32","author":"Ward","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.106.012781_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1081\/DMR-100102338","article-title":"The human CYP3A subfamily: practical considerations","volume":"32","author":"Wrighton","year":"2000","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.106.012781_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF02353474","article-title":"The human drug metabolizing cytochromes P450","volume":"24","author":"Wrighton","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.106.012781_bib41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","article-title":"Inhibition of cytochromes P450 by antifungal imidazole derivatives","volume":"30","author":"Zhang","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.106.012781_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1582-4934.2002.tb00186.x","article-title":"Cytochromes P450 and experimental models of drug metabolism","volume":"6","author":"Zuber","year":"2002","journal-title":"J Cell Mol Med"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624012972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624012972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.106.012781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:18:47Z","timestamp":1739877527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624012972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0090955624012972"],"URL":"https:\/\/doi.org\/10.1124\/dmd.106.012781","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of Site-Specific CYP3A-Mediated Metabolism for Dual Angiotensin and Endothelin Receptor Antagonists in Various in Vitro Systems and in Cynomolgus Monkeys","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.106.012781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}